Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1985-10-28
1992-03-17
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514457, 514456, A61K 3135
Patent
active
050968874
DESCRIPTION:
BRIEF SUMMARY
This application is the national application corresponding to international application No. PCT/AU85/00036 filed Mar. 1, 1985 and designating the United States.
This invention relates to the treatment of high protein oedemas in animals including man, particularly the application of the benzo-pyrones to the skin and mucous membranes.
BACKGROUND OF THE INVENTION
Members of the benzo-pyrone group of drugs are known, and while the drugs have obviously been tested in a large variety of experimental conditions in laboratory animals, they have never been suggested for veterinary use.
Oedema is an abnormal accumulation of fluid in the tissue spaces or cavities of the body. There are five main factors in the formation of generalised oedema and a sixth which plays an important role in the formation of local oedema. They are:
1. Permability of the capillary wall,
2&3. Colloidal osmotic pressure of the plasma proteins in the blood and tissues,
4&5. Hydrostatic pressures in the capillaries and tissues, and
6. Lymphatic obstruction.
Thus oedema is an unusual swelling of the tissue due to an excessive amount of fluid and can be the result of various causes. Thus haematoma, or in other words a bruise, is one of the most common oedemas. The causes of oedema fall naturally into four groups corresponding to the four classes of oedema, thus
1. High-flow low-protein
2. High-flow high-protein
3. Low-flow high-protein, as well as a fourth group of causes of oedema "safety valve insufficiency" which occurs when lymphostasis is superimposed on what would normally be a high flow oedema produced either by excess blood vascular leakage, or the obstruction of a duct of an organ (kidney, pancreas, etc.) the results of which are particularly disastrous for the tissues.
High-protein oedemas are very common in all communities. It has been found that one person in three seeks medical attention every year in South Australia for a condition associated with one. The W.H.O. estimates that 250,000,000 people suffer from lymphoedema and elephantiasis, while 250,000 women in Australia suffer from lymphoedema of the arm, of varying grades of severity, after mastectomy. It is highly probably that the improvement produced by the benzo-pyrone group of drugs, in so many different diseases, is because they have high-protein oedema associated with them. This always causes reduced oxygenation and function of the tissues. If the oedema is reduced, oxygenation and function are improved. While these drugs do not affect the basic diseases, the reduction they produce in associated oedemas improve the function of the tissues and thus the normal healing processes proceed more expeditiously. Examples of this are: lymphoedema, accidental and surgical trauma, haematomas, pancreatitis, hepatitis and cirrhosis.
BRIEF DESCRIPTION OF THE INVENTION
It has been found that the group of benzo-pyrones is highly beneficial in the treatment of oedemas, particularly high protein oedemas.
Thus according to the invention there is provided a method of treating high-protein oedemas in animals including man, by the application of any member of the benzo-pyrone group of drugs to the skin or mucous membranes of the animal.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
It has been shown that these drugs can effectively reduce high protein oedemas and they do this by increasing the normal proteolysis of the tissues and (to some extent) by increasing lymphatic function. They are thus effective in all diseases which have high protein oedema as part of their disorders. While they do not cure any underlying disease, the fact that they reduce the associated high protein oedema means that they relieve much pain and loss of function. In addition all oedemas cause lowered oxygenation and much harm to the tissues. The high protein ones in particular (if prolonged) cause chronic inflammation and thus their removal is of considerable benefit.
The benzo-pyrones are a group of compounds which include a number of sub-groups. They contain the flavonoids and their derivatives, coumarin and its de
REFERENCES:
patent: 3155579 (1964-11-01), Perrault
patent: 3567832 (1971-03-01), Boschetti et al.
patent: 4616033 (1986-10-01), Casley-Smith
T. J. Hardt, et al. Thesis, University of Cincinnati Medical Center (date not known).
T. Lerut, et al., Medikon Nederland 5, p. 1923 (1976).
Remington's Pharmaceutical Sciences; 16th Ed. (1980) pp. 1252-1253.
Lamorna Investments Proprietary Limited
Waddell Frederick E.
Weddington K.
LandOfFree
Treatment of high protein oedemas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of high protein oedemas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of high protein oedemas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1475949